Ocugen(NASDAQ) OCGN

Ocugen, Inc. NASDAQ:OCGN creates gene therapies to treat blindness. These medicines aim to repair or preserve retinal health. The company helps patients with rare eye diseases.

Saving Sight With Gene Therapy

• OCU400: Gene therapy that treats several forms of retinitis pigmentosa by resetting health in the retina; currently in late-stage clinical trials.
• OCU410: Therapy designed to treat geographic atrophy and dry age-related macular degeneration using a single sub-retinal injection.
• OCU410ST: Specialized treatment for Stargardt disease that modulates lipid metabolism and oxidative stress to restore eye health.
• OCU200: Fusion protein undergoing early study for vascular complications like diabetic macular edema and wet macular degeneration.
• OCU500: Inhaled vaccine for COVID-19 being developed in collaboration with the National Institute of Allergy and Infectious Diseases.

Moving Toward the Finish Line

• Completed enrollment for the Phase 3 liMeliGhT trial of OCU400 in 2026 with topline data expected in 2027.
• Received Regenerative Medicine Advanced Therapy designation from the FDA for OCU410 in July 2026 to treat geographic atrophy.
• Finished dosing for the Phase 2/3 pivotal trial of OCU410ST for Stargardt disease in April 2026.
• Secured $130.0 million through a private offering of convertible notes in May 2026 to fund clinical development.

A New Way to Fix Genes

The company uses a modifier gene therapy platform that targets gene networks rather than individual mutations. This gene-agnostic approach allows one treatment to potentially help patients with many different genetic causes for the same disease.

Measuring the Progress

• Net loss reached $24.9 million for the three-month period ended June 30, 2026, compared to $14.7 million in 2025.
• Collaborative arrangement revenue rose to $3.0 million for the six-month period ended June 30, 2026, up $0.2 million year over year.
• Research and development costs hit $21.9 million for the six-month period ended June 30, 2026, up $4.0 million year over year.
• Cash and cash equivalents were $100.1 million as of June 30, 2026.
• Accumulated deficit grew to $452.1 million as of June 30, 2026, due to ongoing clinical research expenses.

Focus on Clinical Results

Ocugen has transitioned from a research-stage startup to a clinical-stage biotechnology firm with several late-stage trials. While development costs remain high, its novel platform offers a broad way to address diverse blinding diseases.